1,187 results on '"Gladman, D."'
Search Results
2. POS0732 SHORT AND LONG-TERM OUTCOMES OF PATIENTS WITH PURE MEMBRANOUS LUPUS NEPHRITIS COMPARED TO PATIENTS WITH PROLIFERATIVE DISEASE
3. Sécurité et efficacité à long terme du tofacitinib chez des patients atteints de rhumatisme psoriasique traités antérieurement par un médicament antirhumatismal biologique (bDMARD)
4. L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST
5. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis
6. Breast Cancer in Systemic Lupus Erythematosus
7. POS1533 BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
8. POS1527 EFFECTS OF APREMILAST ON CHANGES IN CARDIOMETABOLIC PARAMETERS BY DIABETES AND OBESITY STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS
9. POS1110 PATIENT CLUSTERS IDENTIFIED BY MACHINE LEARNING: DATA FROM A POOLED ANALYSIS OF PHASE-3 TRIALS OF SECUKINUMAB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH AXIAL MANIFESTATIONS
10. POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
11. POS0023 PERFORMANCE OF BASDAI VS. ASDAS IN EVALUATING AXIAL INVOLVEMENT IN PATIENTS WITH PSA TREATED WITH GUSELKUMAB: POOLED ANALYSIS OF TWO PHASE 3 STUDIES
12. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
13. AB1093 LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
14. POS1608 MIRNA BIOMARKERS FOR ARTICULAR AND CUTANEOUS RESPONSE TO METHOTREXATE IN PSORIATIC ARTHRITIS
15. AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS
16. AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
17. POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
18. AB1110 EXPLORING LEVELS OF PROTEIN BIOMARKERS IN RESPONSE TO TREATMENT FOR PSORIASIS AND PSORIATIC ARTHRITIS
19. AB1156 METABOLIC DISORDERS AND ABNORMAL DIETARY PATTERNS AND THEIR ASSOCIATION WITH PSORIATIC ARTHRITIS ACTIVITY: THE DIETARY INTERVENTION IN PSA (DIPSA) STUDY
20. POS0019 PREDICTION OF PSORIATIC ARTHRITIS TOOL (PRESTO): DEVELOPMENT AND PERFORMANCE OF A NEW SCORING SYSTEM FOR PSORIATIC ARTHRITIS RISK
21. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
22. Supplementary to: Psoriatic arthritis.
23. POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
24. POS1080 CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY
25. OP0030 ASSOCIATION OF TRADITIONAL AND DISEASE-RELATED RISK FACTORS WITH CARDIOVASCULAR EVENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS
26. AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
27. AB0888 Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
28. POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS
29. AB0929 Is there a correlation between skin severity and joint activity in Psoriatic Arthritis (PsA)?
30. POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
31. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
32. OP0140 IMPACT OF TIME TO REMISSION, FLARES AND TIME ON IMMUNOSUPPRESSIVES ON THE ESTIMATED GLOMERULAR FILTRATION RATE IN LUPUS NEPHRITIS
33. POS1093 EFFECT OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON DEPRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS IN A LONGITUDINAL COHORT
34. AB0895 Residual burden and disease activity of Canadian PsA patients treated with advanced therapies: preliminary results from a multiple registry analysis (UNISON-PsA)
35. OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB
36. AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial
37. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
38. Assessing Prognosis in Rheumatoid Arthritis Using Monoclonal Antibodies and Flow Cytometry
39. Efficacité de l’ixékizumab sur la douleur rachidienne, l’activité de la maladie et la qualité de vie chez des patients atteints de rhumatisme psoriasique présentant des symptômes évocateurs d’une atteinte axiale
40. Efficacité d’upadacitinib chez des patients atteints de rhumatisme psoriasique actif ayant un nombre d’articulations gonflées élevé ou faible : analyse de sous-groupes de 2 études de phase 3 (SELECT-PsA 1 et SELECT-PsA 2)
41. Psoriatic arthritis
42. PE.Lu-093 - L’aprémilast, un inhibiteur oral de la phosphodiestérase 4, est associé à une amélioration à long terme (104 sem.) de la fatigue chez les patients atteints de rhumatisme psoriasique : résultats regroupés de 3 études de phase III, contrôlées, randomisées
43. PE.Lu-044 - Traitement du rhumatisme psoriasique par certolizumab pegol : Résultats à 4 ans de l’étude RAPID-PsA
44. O.30 - Abatacept dans le traitement du rhumatisme psoriasique actif : résultats à 24 semaines d’une étude de phase III
45. O.104 - Étude de phase 3 randomisée, en double aveugle, évaluant l’efficacité et la tolérance de l’ixekizumab, l’adalimumab et du placebo chez des patients avec un rhumatisme psoriasique actif et naïfs de traitements de fond biologiques
46. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24□weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
47. AB0557 ACHIEVING TREATMENT TARGETS IN PSORIATIC ARTHRITIS WITH APREMILAST IN CANADIAN PRACTICE: REAL WORLD RESULTS FROM APPRAISE
48. AB0550 EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2)
49. OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021
50. POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.